Serina Therapeutics SEC Filings

Insider transaction summary (SEC Form 4)

On 07/28/2025, Serina Therapeutics (SER) Chief Scientific Officer Dr. Randall Moreadith exercised 6,500 stock options at a strike of $0.06 and immediately sold the resulting shares in the open market. The weighted-average sale price was $5.89 (price range $6.02–$5.60). Net of the option cost, the insider realized roughly $38 k in gross proceeds, while the company received only ~$390 from the option exercise.

After the transactions the officer now holds 0 common shares directly, but still owns 488,686 fully-vested options expiring 05/06/2031. The divestment is immaterial relative to SER’s share count and does not alter overall insider exposure, yet it removes all direct share ownership for this executive.

No other securities, derivatives or accompanying disclosures were reported.

Serina Therapeutics, Inc. (NYSE American: SER) filed a Form 8-K on 29-Jul-2025 under Item 7.01 (Regulation FD). The filing furnishes—rather than files—a press release and an investor presentation (Exhibits 99.2 and 99.1) that spotlight the advancement of SER-270 (POZ-VMAT2i), a proprietary POZ-conjugated VMAT2 inhibitor in development for tardive dyskinesia. CEO Steve Ledger will discuss the program during the BTIG Virtual Biotechnology Conference on the same day using the accompanying presentation materials. No financial results, clinical data, guidance, or other material transactions are disclosed, and the company expressly states the furnished information will not be incorporated into future Securities Act filings unless specifically referenced. No other Items were reported.

Form 4 snapshot – Serina Therapeutics (SER): On 07/21/2025 Chief Scientific Officer Randall Moreadith exercised 6,500 fully-vested options at an exercise price of $0.06 and immediately sold the same 6,500 common shares in the open market. The weighted-average sale price was $5.34 (range $5.31-$5.40), generating gross proceeds of roughly $34.7 k and eliminating his direct common-stock position, which now stands at 0 shares. He retains 495,186 options after the transaction. The filing reflects a routine option-exercise-and-sell pattern rather than large-scale disposal, but it does reduce immediate share ownership by a named executive.

JPMorgan Chase Financial Company LLC is offering Capped Buffered Return Enhanced Notes linked to the S&P 500 Index (SPX). The notes are senior unsecured obligations of the issuer, fully and unconditionally guaranteed by JPMorgan Chase & Co., and are expected to price on or about July 31 2025, settle on August 5 2025, and mature on August 6 2026.

Key economic terms

• Upside participation: 2.0× any positive Index return.
• Maximum Return: at least 11.25% of principal (i.e. maximum payment of ≥ $1,112.50 per $1,000 note).
• Buffer Amount: 10% – principal protected as long as the Index does not decline by more than 10% from the Initial Value.
• Downside exposure: For losses beyond the 10% buffer, investors lose 1% of principal for every 1% decline in the Index, up to a maximum loss of 90%.
• Denominations: $1,000 and integral multiples.
• CUSIP: 48136FQF2.
• Estimated value (if priced today): $997 per $1,000 note; final estimate will not be below $980.

Payout mechanics

• Positive scenario: If the Final Value ≥ Initial Value, payment = $1,000 + ($1,000 × Index Return × 2.0), capped at the Maximum Return.
• Flat to moderate decline (0% to –10%): principal is returned.
• Decline > 10%: Payment = $1,000 + [$1,000 × (Index Return + 10%)], exposing the investor to a dollar-for-dollar loss beyond the buffer.

Illustrative outcomes

• Index +5% → Investor receives $1,100 (10% return).
• Index +25% → Capped at $1,112.50 (11.25% return).
• Index –15% → Investor receives $950 (–5% return).
• Index –50% → Investor receives $600 (–40% return).

Risk highlights

• Principal risk: up to 90% loss at maturity.
• Return cap: upside limited to ≤ 11.25% despite 2× leverage.
• Credit risk: payments rely on JPMorgan Financial and JPMorgan Chase & Co.
• No periodic interest or dividends; investors forgo S&P 500 dividends.
• Liquidity: notes will not be listed; secondary trading, if any, only through JPMS and likely at prices below issue price.
• Estimated value below issue price reflects hedging and structuring costs.

Fees & distribution

The notes are sold through fee-based advisory accounts; affiliated or unaffiliated broker-dealers will forgo traditional sales commissions. Proceeds to issuer are 100% of face value, but investors should understand that embedded structuring and hedging costs reduce economic value.

Tax treatment

The issuer expects to treat the notes as open transactions (prepaid forward contracts) for U.S. federal income-tax purposes, producing long-term capital gain or loss if held > 1 year, but this treatment is not certain and may change with future IRS guidance. Non-U.S. Holders are expected to be outside the scope of Section 871(m), subject to final confirmation at pricing.

Investor profile

The product targets investors with a moderately bullish view on U.S. large-cap equities over the 1-year term, who are willing to cap upside at ~11% in exchange for a 10% buffer and are comfortable bearing both market and issuer credit risk.

Gladstone Investment Corporation (NASDAQ: GAIN) – 2025 Definitive Proxy Statement highlights

• Annual Meeting: Thursday, August 7, 2025 at 11:00 a.m. ET via webcast (www.virtualshareholdermeeting.com/GAIN2025). Record date: June 11, 2025 (36,921,165 shares outstanding).

• Proposals up for vote:

• Proposal 1: Elect two directors—David Gladstone (Chairman & CEO, interested) and John H. Outland (independent)—for terms expiring at the 2028 meeting.
• Proposal 2: Ratify PricewaterhouseCoopers LLP (PwC) as independent registered public accounting firm for fiscal year ending March 31, 2026.

• Board composition: Seven members; five independent (71%). Lead Independent Director: Walter H. Wilkinson. Board is staggered into three classes; independence evaluated under Nasdaq and 1940 Act rules.

• Diversity snapshot (June 30 2025): 3 female / 3 male / 1 undisclosed; 3 military veterans; racial/ethnic mix includes Hispanic/Latinx and multiracial representation.

• Governance structure: Combined Chair/CEO role held by founder David Gladstone; Lead Independent Director mitigates oversight concerns. Key committees—Audit, Compensation, Ethics/Nominating, Valuation—are fully independent. Audit Committee members qualify as “audit committee financial experts.”

• Audit firm & fees: PwC has served since 2006. FY 2025 audit-related fees total $674k (up 8.5% YoY), with $113k categorized as audit-related (ATM program & debt offering).

• External management economics: Adviser earns 2% base fee on average gross assets plus incentive fees (20% over 8.75% annualized hurdle). FY 2025 payments: $23.7 million to Adviser; $1.9 million to Administrator.

• Director compensation (FY 2025): Independent directors received $25k base retainer plus meeting/committee fees; top earner was John H. Outland at $52k from the Company ($245k across Gladstone fund complex).

• Share ownership: Insiders/directors own 2.40% of common stock; David Gladstone holds the largest stake (667,630 shares, 1.81%). No outside holder exceeds 5%.

• Voting mechanics: Directors elected by plurality; PwC ratification requires majority of shares present. Broker non-votes count toward quorum, not outcome (non-routine for Proposal 1, routine for Proposal 2).

FormFactor Inc. (FORM) has filed a Form 144 notice indicating an intended insider sale of up to 4,000 common shares through Morgan Stanley Smith Barney on or about 01 Jul 2025. Based on the filing’s stated aggregate market value of $136,106.80, the planned transaction represents roughly 0.005 % of the company’s 77,076,642 shares outstanding, implying minimal ownership dilution or trading-volume impact.

The seller, identified in the past-sales table as Mike Slessor, acquired the shares as performance stock on 19 Jul 2022. The document notes no gift status or non-cash consideration. Within the preceding three months, the same individual sold 8,000 shares in two tranches (01 May 2025 and 02 Jun 2025) for combined gross proceeds of $246,188.80. Adding the upcoming sale would bring the rolling three-month total to 12,000 shares.

The filing contains the standard representation that the seller is not in possession of undisclosed material adverse information and provides no indication of additional planned transactions beyond the stated amount. Given the modest size relative to market float and the routine nature of a Rule 144 filing, immediate financial impact appears limited; however, continued insider selling can sometimes influence investor sentiment.

Campbell Soup Company (CPB) – Form 4 filing dated 06/30/2025

Director Maria Teresa Hilado reported the acquisition of 1,459.54 phantom stock units on 06/26/2025. Each unit is economically equivalent to one share of Campbell common stock but settles in cash under the company’s Supplemental Retirement Plan when the director leaves the board. Following the transaction, Hilado’s total phantom stock balance stands at 32,860.64 units, which includes 338.02 units accumulated via dividend reinvestment since her prior report.

The transaction was coded “A” (award) at a stated price of $0, indicating a routine, non-market grant typically tied to director compensation or fee deferrals rather than an open-market purchase. Because phantom stock does not involve the issuance of new shares or direct cash outlay by the insider, the filing has limited immediate impact on CPB’s share count, liquidity, or public float.